Literature DB >> 16967489

Predictability of disease progression in amyotrophic lateral sclerosis.

Adam Czaplinski1, Albert A Yen, Ericka P Simpson, Stanley H Appel.   

Abstract

The aim of this study was to determine the predictors of disease progression in a group of 832 patients with the diagnosis of definite or probable amyotrophic lateral sclerosis (ALS). Disease progression was defined as the time to 20-point change in Appel ALS (AALS) score. The effects of individual prognostic factors on disease progression were assessed with the Kaplan-Meier life-table method. In addition, the prognostic value of each factor was estimated using both univariate and multivariate Cox proportional hazard analyses. The median time to a 20-point change in AALS score in our patient population was 9 months. Age, site of symptom onset, time between first symptom and first examination, total AALS score at first examination, and AALS preslope (rate of disease progression between first symptom and first examination) were significant and independent covariates of disease progression in our population. Identification of predictors of disease progression will facilitate better design of therapeutic trials, permitting the use of disease progression as a primary endpoint and improving baseline stratification of patient populations.

Entities:  

Mesh:

Year:  2006        PMID: 16967489     DOI: 10.1002/mus.20658

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  23 in total

1.  Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression.

Authors:  Robert Küffner; Neta Zach; Raquel Norel; Johann Hawe; David Schoenfeld; Liuxia Wang; Guang Li; Lilly Fang; Lester Mackey; Orla Hardiman; Merit Cudkowicz; Alexander Sherman; Gokhan Ertaylan; Moritz Grosse-Wentrup; Torsten Hothorn; Jules van Ligtenberg; Jakob H Macke; Timm Meyer; Bernhard Schölkopf; Linh Tran; Rubio Vaughan; Gustavo Stolovitzky; Melanie L Leitner
Journal:  Nat Biotechnol       Date:  2014-11-02       Impact factor: 54.908

Review 2.  Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology and survival.

Authors:  John D Beard; Freya Kamel
Journal:  Epidemiol Rev       Date:  2014-10-31       Impact factor: 6.222

3.  Decreased brain activation to tongue movements in amyotrophic lateral sclerosis with bulbar involvement but not Kennedy syndrome.

Authors:  Bahram Mohammadi; Katja Kollewe; Amir Samii; Klaus Krampfl; Reinhard Dengler; Thomas F Münte
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

4.  ALS-CSF-induced structural changes in spinal motor neurons of rat pups cause deficits in motor behaviour.

Authors:  Sanjay Das; A Nalini; T R Laxmi; T R Raju
Journal:  Exp Brain Res       Date:  2020-11-10       Impact factor: 1.972

5.  MR spectroscopy findings in early stages of motor neuron disease.

Authors:  M M van der Graaff; C Lavini; E M Akkerman; Ch B Majoie; A J Nederveen; A H Zwinderman; F Brugman; L H van den Berg; J M B V de Jong; M de Visser
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-26       Impact factor: 3.825

Review 6.  Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?

Authors:  Neta Zach; David L Ennist; Albert A Taylor; Hagit Alon; Alexander Sherman; Robert Kueffner; Jason Walker; Ervin Sinani; Igor Katsovskiy; Merit Cudkowicz; Melanie L Leitner
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Prognosis and epidemiology of amyotrophic lateral sclerosis: Analysis of a clinic population, 1997-2011.

Authors:  Kim Traxinger; Crystal Kelly; Brent A Johnson; Robert H Lyles; Jonathan D Glass
Journal:  Neurol Clin Pract       Date:  2013-08

8.  Progression in primary lateral sclerosis: a prospective analysis.

Authors:  Mary Kay Floeter; Reversa Mills
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

9.  Blood Lead, Bone Turnover, and Survival in Amyotrophic Lateral Sclerosis.

Authors:  Fang Fang; Tracy L Peters; John D Beard; David M Umbach; Jean Keller; Daniela Mariosa; Kelli D Allen; Weimin Ye; Dale P Sandler; Silke Schmidt; Freya Kamel
Journal:  Am J Epidemiol       Date:  2017-11-01       Impact factor: 4.897

10.  Quantitative strength testing in ALS clinical trials.

Authors:  Jeremy M Shefner; Dawei Liu; Melanie L Leitner; David Schoenfeld; Donald R Johns; Toby Ferguson; Merit Cudkowicz
Journal:  Neurology       Date:  2016-07-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.